It is hypothesized that selected homeostatic gene-expression states may be partially restored in experimental cancer models through the integration of quantum-informed AI, CRISPR gene alteration, and nanomaterial delivery, which could support future cancer therapies that move beyond tumor suppression toward controlled modulation of malignant cell states, although substantial preclinical and clinical validation remains necessary.
Bladder cancer (BCa) exhibits significant genetic and phenotypic variability. This variability suggests that various tumor subtypes could be influenced by several biomarkers and signaling pathways, which presents a problem for monotherapy strategies. Despite the initial effectiveness of traditional therapies, BCa's hig...
Swarupananda Mukherjee, D. Karati, Sinjini Sarkar et al.· Nanomedicine· 0 citations
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology is a cutting-edge genome editing tool based on the adaptive immune mechanism of prokaryotes. This system, which operates through three key stages‒adaptation, expression, and interference‒offers high precision and efficiency in genetic...
M. Omarov, E. Karacheva, M. M. Arapieva et al.· Сибирский научный медицински...· 0 citations
The mechanisms of CRISPR-Cas9 gene editing, recent technological advancements, and prospects for cancer management are explored and insights into strategies for precise delivery, improved targeting accuracy, and the regulatory considerations surrounding CRISPR-Cas9 for oncological applications are provided.
Nikhil Rawal, Shruti Batra, Tanu Sharma et al.· Current pharmaceutical desig...· 0 citations
An overview of the CRISPR screen methodology, which involves introducing guide RNAs targeting specific genes into cells, followed by phenotype selection and analysis, is presented, providing valuable insights into gene function and potential therapeutic targets.
Xinyue Zhou, Rui Lu· Methods in molecular biology· 0 citations
The strategies detailed here define a next-generation precision-oncology paradigm capable of anticipating tumor evolution, overcoming resistance, and preventing metastatic relapse, by uniting AI-guided design, circadian reprogramming, dormancy eradication, and logic-gated delivery.
Anmar Ghanim Taki, Abdulkareem Shareef, Vimal Arora et al.· Iranian Journal of Basic Med...· 0 citations
Overall, CRISPR-based technologies show considerable potential to support precision oncology in prostate cancer by enabling molecularly informed therapeutic strategies and addressing treatment resistance, although challenges related to delivery, off-target effects, tumor heterogeneity, immunogenicity, and clinical tran...
Vaibhavkumar Patel, Pratichi Singh, S. Dutta et al.· Critical reviews in oncology...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
